Nucleos(t)ide analogue therapy: The role of tenofovir alafenamide.
TAF
chronic hepatitis B
hepatitis B virus
nucleos(t)ide analogues
tenofovir
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
22
02
2021
accepted:
22
02
2021
entrez:
22
6
2021
pubmed:
23
6
2021
medline:
29
6
2021
Statut:
ppublish
Résumé
Chronic hepatitis B virus (HBV) infection remains an important global health problem, and may be difficult to manage in clinical practice. Nucleos(t)ide analogues (NAs) with a high barrier to resistance (entecavir [ETV], tenofovir disoproxil fumarate [TDF] and tenofovir alafenamide [TAF]) are the most frequently used HBV treatments because of their long-term effectiveness and tolerability. ETV may be less effective in patients with lamivudine-resistant strains, and TDF is associated with impaired renal function and reductions in bone mineral density. TAF, a new tenofovir prodrug, has been developed to overcome the less favourable safety profile of TDF. TAF is more stable in plasma, and higher tenofovir levels are achieved within cells at lower doses than with TDF. Several registration and real-life studies, performed up to week 144 of treatment, have shown that TAF is at least as effective as TDF, with higher rates of ALT normalization and significantly fewer kidney disturbances and changes in bone mineral density. No emergence of drug resistance has been found with TAF use. The main limitation to prescribing TAF is its price. The European Association for the Study of the Liver has suggested selecting TAF or ETV instead of TDF in patients >65 years old and in those with a risk of osteoporosis or renal abnormalities, and to prescribe TAF rather than ETV in patients previously exposed to NAs.
Substances chimiques
Antiviral Agents
0
Tenofovir
99YXE507IL
tenofovir alafenamide
EL9943AG5J
Adenine
JAC85A2161
Alanine
OF5P57N2ZX
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9-14Informations de copyright
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Lampertico P, Agarwal K, Berg T, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370-398.
McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009;49:S45-S55.
Trépo C, Chan HLY, Lok A. Hepatitis B virus infection. Lancet. 2014;384:2053-2063.
Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560-1599.
Marcellin P, Wong DK, Sievert W, et al. Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection. Liver Int. 2019;39(10):1868-1875.
Delaney WE, Ray AS, Yang H, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother. 2006;50:2471-2477.
Birkus G, Bam RA, Willkom M, et al. Intracellular activation of tenofovir alafenamide and the effect of viral and host protease inhibitors. Antimicrob Agents Chemother. 2016;60(1):316-322.
Agarwal K, Fung SK, Nguyen TT, et al. Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. J Hepatol. 2015;62(3):533-540.
Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. lancet Gastroenterol Hepatol. 2016;1(3):196-206.
Chan HLY, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. lancet Gastroenterol Hepatol. 2016;1(3):185-195.
Agarwal K, Brunetto M, Seto WK, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018;68(4):672-681.
Chan HLY, Lim Y-S, Seto WWK, et al. Three-year efficacy and safety of tenofovir alafenamide (TAF) compared to tenofovir disoproxil fumarate (TDF) in HBeAg-negative and HBeAg-positive patients with chronic hepatitis B. Hepatol. 2018;68:227A.
Seto WKW, Buti M, Izumi N, et al. Bone and renal safety are improved in chronic HBV patients 1 year after switching to tenofovir alafenamide (TAF) from tenofovir disoproxil fumarate (TDF). Hepatology. 2018;68:240A.
Lampertico P, Buti M, Ramji A, et al. A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results. J Hepatol. 2020;73:S67-S68.
Kaneko S, Kurosaki M, Tamaki N, et al. Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate. J Gastroenterol Hepatol. 2019;34(11):2004-2010.
Gane E, Seto W-K, Janssen H, et al. Safety and efficacy at 1 year after switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in chronic HBV patients with risk factors for TDF use. J Hepatol. 2018;68:S87.
LIM Y-S, Gwak G-Y, Choi J, et al. Tenofovir alafenamide (TAF) for multiple drug-resistant Hepatitis B: a randomized, multicenter trial to evaluate the efficacy and safety of switching from TDF to TAF vs. continuing TDF in CHB patients with genotypic resistance to ETV and/or ADV. Hepatol. 2019;70:315A-316A.
Ogawa E, Nomura H, Nakamuta M, et al. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B. Liver Int. 2020;40:1578-1589.
Tenofovir alafenamide prescribing information. https://www.ema.europa.eu/en/documents/product-information/vemlidy-epar-product-information_en.pdf
Fung S, Brunetto M, Buti M, et al. Safety and efficacy of tenofovir alafenamide in geriatric patients with chronic hepatitis B: experience from four ongoing phase 2 and phase 3 clinical trials. J Hepatol. 2020;73:S883-S884.
Li B, Gu Y, Wang Y, et al. Tenofovir (TFV) or tenofovir alafenamide (TAF) concentration in breast milk and infants’ cord blood, with tenofovir disoproxil fumarate (TDF) or TAF treatment in pregnancy. Hepatol Int. 2020;14:S78.
Lim Y-S, Lin C, Heo J, et al. Safety and efficacy of switching to Tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with hepatic impairment: week 48 results from a phase 2 open-label study. J Hepatol. 2020;73:S872.
Roade L, Loglio A, Borghi M, et al. Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamide. Dig Liver Dis. 2020;52(10):1164-1169.
Curry M, Bae H, Dieterich D, et al. Differential tenofovir alafenamide (TAF) adoption in HBV-infected populations; assessment of care in US clinical practice. J Hepatol. 2020;73:S876.
Papatheodoridis G, Mimidis K, Manolakopoulos S, et al. Real-world experience from tenofovir alafenamide use in chronic hepatitis B: an Hellenic multicenter real-life clinical study (HERACLIS-TAF). J Hepatol. 2020;73:S865-S866.
Dusheiko G, Lim J, Liou I, et al. Cost-effectiveness analysis of first-line administration of tenofovir alafenamide (TAF), a novel nucleotide reverse transcrip-tase inhibitor (NRTI), for the management of chronic hepatitis b (CHB) in the united states (us). Value Heal. 2017;20:A78.
Pan C, Brunetto M, Hui A, et al. Improved bone and renal safety at 1 year after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: results from 2 phase 3 studies in HBeAg-positive and HBeAg-negative patients with chronic hepatitis B. Published online. 2017; https://www.natap.org/2017/AASLD/AASLD_55.htm
Buti M, Lampertico P, Lim Y-S, et al. Safety and efficacy at 48 weeks after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in chronic HBV patients with risk factors for TDF use. Hepatol. 2019;70:301A.
Lee M, Lee SM, Bernstein DE. Switching drom Tenofovir disoproxil to Tenofovir alafenamide: assessing the change in renal function in hepatitis B patients. Hepatol. 2019;70:316A.
Ahn SH, Kao J-H, Hann H-W, et al. 48-week safety and efficacy of switching to tenofovir alafenamide (TAF) from tenofovir disoproxil fumarate (TDF) in chronic HBV Asian patients with TDF risk factors (RF). Hepatol Int. 2020;14:S87.